Skip to main content
Swing Capital

Astrazeneca Pharma India Ltd

NSE: ASTRAZEN BSE: 506820Pharma

AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products.[1]

₹8,550
52W: ₹7552 — ₹10691
PE 103 · Book ₹320 · +2572% vs book
Market Cap₹21,375 Cr
Stock P/E103Price to Earnings
ROCE33.4%Return on Capital
ROE23.6%Return on Equity
Div. Yield0.38%Face Value ₹2

Strengths

  • +Company is almost debt free.
  • +Company is expected to give good quarter
  • +Company has delivered good profit growth of 19.4% CAGR over last 5 years
  • +Company has been maintaining a healthy dividend payout of 48.8%

Weaknesses

  • −Stock is trading at 26.2 times its book value

Shareholding Pattern

Promoters75%
FIIs2.78%
DIIs5.79%
Public16.42%
CategoryJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters75%75%75%75%75%75%75%75%
FIIs2.79%2.9%▲0.12.92%▲0.02.89%▼0.03.03%▲0.12.74%▼0.32.71%▼0.02.78%▲0.1
DIIs4.99%5.08%▲0.15.21%▲0.14.65%▼0.64.55%▼0.15.26%▲0.75.55%▲0.35.79%▲0.2
Public17.21%17.02%▼0.216.85%▼0.217.45%▲0.617.41%▼0.017%▼0.416.73%▼0.316.42%▼0.3

Financial Statements

MetricSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales311306383388408440480526559612
Expenses258291334349355363394445484567
Operating Profit53154938537786817545
OPM %17%5%13%10%13%17%18%15%13%7%
Net Profit521639-12383158565433
EPS ₹20.956.3215.79-4.7215.3712.3423.322.3321.6913.04

AI Insights

Revenue Trend

TTM revenue at ₹2,177Cr, up 26.9% YoY. OPM at 13%.

Debt Position

Borrowings at ₹35Cr. Debt-to-equity ratio: 0.04x. Healthy balance sheet.

Institutional Flow

DIIs: 5.79% (+3.88pp change). FIIs: 2.78% (+0.10pp change). Promoters hold 75%.

Margin & Efficiency

ROCE improving from -12% (Mar 2014) to 33% (Mar 2025). Working capital days: 22.

Valuation

PE 103x with 33.4% ROCE. Price is 2572% above book value of ₹320. Dividend yield: 0.38%.

Recent Announcements